Aims and objectives
To assess the impact of CT scan-based volumetric analysis on radiologic and clinical outcomes of patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE).
Learning Objectives:
The aims of this electronic presentation are:
• Reflect the technical considerations about CT-based volumetric analysis;
• Understand HCC lesions behavior on dynamic multi-phase CT scans;
• Assess outcomes of percutaneous treatment of HCC using TACE technique.
• Assess the impact of pre-operative CT-based volumetric analysis predicting outcomes of TACE on patients with HCC;
• Transfer the practical hints...
Methods and materials
Patient Population:
Over a 41-month period,
65 TACE procedures were performed in 38 patients.
Baseline dynamic CT-based volumetric analysis was performed in 15 patients.
CT-based Volumetric Analysis details:
Portal venous phase series of images from the preoperative dynamic multi-phase CT scans were used for total liver volumetry.
Set of axial images with a slice thickness of 3-5 mm was used for the analysis.
Three observers (JG,
DT and JQ,
observers 1,
2,
and 3,
respectively) performed liver volumetry for allpatients on an iMac using OsiriX®/...
Results
Baseline median total hepatic volume was 1444 ml (IQR,
1240-2034 ml) with a median tumor volume of 623 ml (IQR,
41-1019 ml) and a median residual hepatic volume of 965 ml (IQR,
779-1365 ml) (Figure 6).
All procedures were performed using doxorubicin-polyvinyl alcohol (PVA) microspheres conjugates.
Patients with liver-related adverse events (3[20%]) were found to have lower baseline residual hepatic volumes (174 ml [IQR,
36-312 ml] versus 1219 ml [IQR,
847-1400 ml]) (p=0.05) (Figure 7).
Residual volume was found to be correlated with ALT serum...
Conclusion
Baseline residual hepatic volume was associated with higher incidence of liver-related adverse outcomes and liver function impairment.
Baseline tumor volume,
however,
failed to predict adverse radiological outcomes.
The role of CT-based volumetric analysis needs further investigation on the prediction of outcomes after TACE.
References
1. Ferlay J,
Soerjomataram I,
Dikshit R,
Eser S,
Mathers C,
Rebelo M,
et al.
Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012.
Int J Cancer 2015;136:E359-86.
2. Choo SP,
Tan WL,
Goh BK,
Tai WM,
Zhu AX.
Comparison of hepatocellular carcinoma in Eastern versus Western populations.
Cancer 2016.
3. Petrick JL,
Kelly SP,
Altekruse SF,
McGlynn KA,
Rosenberg PS.
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
J Clin Oncol 2016;34:1787-94.
4. Noone AM,
Cronin...